Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments
Go back to Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments| (NASDAQ: NTLA) | Delayed: 12.87 -0.24 (1.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.11 | 52 Week High | $30.40 | |||
| Open | $13.11 | 52 Week Low | $11.86 | |||
| Day High | $13.49 | P/E | N/A | |||
| Day Low | $12.68 | EPS | $0.00 | |||
| Volume | 3,437,215 | |||||
| Regeneron (NASDAQ: REGN) | Delayed: 794.19 -13.52 (1.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.71 | 52 Week High | $592.36 | |||
| Open | $809.40 | 52 Week Low | $325.35 | |||
| Day High | $809.40 | P/E | 208.45 | |||
| Day Low | $789.08 | EPS | $3.81 | |||
| Volume | 487,735 | |||||
